Selected research
Industry Research
Gastrointestinal Cancer Drugs Industry Research Report 2026
Market perspective
The global Gastrointestinal Cancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gastrointestinal Cancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gastrointestinal Cancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gastrointestinal Cancer Drugs include Sanofi, Johnson & Johnson Private, Novartis, Roche, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gastrointestinal Cancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (g), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/g) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastrointestinal Cancer Drugs Market by Company
Sanofi
Johnson & Johnson Private
Novartis
Roche
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb Company
Celgene Corporation
Amgen & Amgen Ireland
Gastrointestinal Cancer Drugs Segment by Type
Oncology
Radiology
Others
Gastrointestinal Cancer Drugs Segment by Application
Specialized Cancer Treatment Centers
Clinics
Hospitals
Ambulatory Surgical Centers
Gastrointestinal Cancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gastrointestinal Cancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gastrointestinal Cancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gastrointestinal Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oncology
- Radiology
- Others
Applications
- Specialized Cancer Treatment Centers
- Clinics
- Hospitals
- Ambulatory Surgical Centers
Companies covered
- Sanofi
- Johnson & Johnson Private
- Novartis
- Roche
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Bristol-Myers Squibb Company
- Celgene Corporation
- Amgen & Amgen Ireland
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gastrointestinal Cancer Drugs Market Size (2021-2032)
- 2.2.2 Global Gastrointestinal Cancer Drugs Sales (2021-2032)
- 2.2.3 Global Gastrointestinal Cancer Drugs Market Average Price (2021-2032)
- 2.3 Gastrointestinal Cancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oncology
- 2.3.3 Radiology
- 2.3.4 Others
- 2.4 Gastrointestinal Cancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Specialized Cancer Treatment Centers
- 2.4.3 Clinics
- 2.4.4 Hospitals
- 2.4.5 Ambulatory Surgical Centers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gastrointestinal Cancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gastrointestinal Cancer Drugs Sales (g) of Manufacturers (2021-2026)
- 3.3 Global Gastrointestinal Cancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Gastrointestinal Cancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Gastrointestinal Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gastrointestinal Cancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gastrointestinal Cancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Gastrointestinal Cancer Drugs, Established Date
- 3.9 Global Gastrointestinal Cancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Gastrointestinal Cancer Drugs Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson Private
- 4.2.1 Johnson & Johnson Private Company Information
- 4.2.2 Johnson & Johnson Private Business Overview
- 4.2.3 Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Private Gastrointestinal Cancer Drugs Product Portfolio
- 4.2.5 Johnson & Johnson Private Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Gastrointestinal Cancer Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Gastrointestinal Cancer Drugs Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Eli Lilly and Company
- 4.5.1 Eli Lilly and Company Company Information
- 4.5.2 Eli Lilly and Company Business Overview
- 4.5.3 Eli Lilly and Company Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eli Lilly and Company Gastrointestinal Cancer Drugs Product Portfolio
- 4.5.5 Eli Lilly and Company Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Gastrointestinal Cancer Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Gastrointestinal Cancer Drugs Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Bristol-Myers Squibb Company
- 4.8.1 Bristol-Myers Squibb Company Company Information
- 4.8.2 Bristol-Myers Squibb Company Business Overview
- 4.8.3 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product Portfolio
- 4.8.5 Bristol-Myers Squibb Company Recent Developments
- 4.9 Celgene Corporation
- 4.9.1 Celgene Corporation Company Information
- 4.9.2 Celgene Corporation Business Overview
- 4.9.3 Celgene Corporation Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Celgene Corporation Gastrointestinal Cancer Drugs Product Portfolio
- 4.9.5 Celgene Corporation Recent Developments
- 4.10 Amgen & Amgen Ireland
- 4.10.1 Amgen & Amgen Ireland Company Information
- 4.10.2 Amgen & Amgen Ireland Business Overview
- 4.10.3 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product Portfolio
- 4.10.5 Amgen & Amgen Ireland Recent Developments
5 Global Gastrointestinal Cancer Drugs Market Scenario by Region
- 5.1 Global Gastrointestinal Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gastrointestinal Cancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Gastrointestinal Cancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Gastrointestinal Cancer Drugs Sales by Region: 2027-2032
- 5.3 Global Gastrointestinal Cancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Gastrointestinal Cancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Gastrointestinal Cancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Gastrointestinal Cancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Gastrointestinal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Gastrointestinal Cancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gastrointestinal Cancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Gastrointestinal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Gastrointestinal Cancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gastrointestinal Cancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gastrointestinal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gastrointestinal Cancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gastrointestinal Cancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Gastrointestinal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Gastrointestinal Cancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Gastrointestinal Cancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gastrointestinal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gastrointestinal Cancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gastrointestinal Cancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Gastrointestinal Cancer Drugs Sales by Type (2021-2032) & (g)
- 6.1.2 Global Gastrointestinal Cancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Gastrointestinal Cancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Gastrointestinal Cancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gastrointestinal Cancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Gastrointestinal Cancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gastrointestinal Cancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Gastrointestinal Cancer Drugs Sales by Application (2021-2032) & (g)
- 7.1.2 Global Gastrointestinal Cancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Gastrointestinal Cancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Gastrointestinal Cancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gastrointestinal Cancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Gastrointestinal Cancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gastrointestinal Cancer Drugs Value Chain Analysis
- 8.1.1 Gastrointestinal Cancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gastrointestinal Cancer Drugs Production Mode & Process
- 8.2 Gastrointestinal Cancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gastrointestinal Cancer Drugs Distributors
- 8.2.3 Gastrointestinal Cancer Drugs Customers
9 Global Gastrointestinal Cancer Drugs Analyzing Market Dynamics
- 9.1 Gastrointestinal Cancer Drugs Industry Trends
- 9.2 Gastrointestinal Cancer Drugs Industry Drivers
- 9.3 Gastrointestinal Cancer Drugs Industry Opportunities and Challenges
- 9.4 Gastrointestinal Cancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst